Vivani Medical (NASDAQ:VANI) Director Acquires $1,999,999.48 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams bought 1,351,351 shares of the stock in a transaction on Tuesday, January 27th. The stock was purchased at an average cost of $1.48 per share, for a total transaction of $1,999,999.48. Following the acquisition, the director owned 27,915,460 shares of the company’s stock, valued at $41,314,880.80. This trade represents a 5.09% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Gregg Williams also recently made the following trade(s):

• On Thursday, January 15th, Gregg Williams purchased 1,737,765 shares of Vivani Medical stock. The shares were purchased at an average price of $1.14 per share, with a total value of $1,981,052.10.
• On Monday, December 15th, Gregg Williams purchased 1,737,765 shares of Vivani Medical stock. The shares were acquired at an average cost of $1.14 per share, with a total value of $1,981,052.10.
• On Saturday, November 15th, Gregg Williams acquired 1,737,764 shares of Vivani Medical stock. The stock was acquired at an average price of $1.14 per share, for a total transaction of $1,981,050.96.

Vivani Medical Trading Up 6.2%

NASDAQ VANI traded up $0.09 during trading hours on Wednesday, hitting $1.47. 794,335 shares of the company’s stock traded hands, compared to its average volume of 349,618. The business’s fifty day moving average price is $1.35 and its two-hundred day moving average price is $1.39. The firm has a market capitalization of $106.87 million, a P/E ratio of -3.26 and a beta of 3.07. Vivani Medical, Inc. has a 52 week low of $0.91 and a 52 week high of $1.92.

Vivani Medical (NASDAQ:VANI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. On average, sell-side analysts expect that Vivani Medical, Inc. will post -0.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on VANI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. Wall Street Zen upgraded Vivani Medical to a “sell” rating in a research note on Saturday, November 22nd. Finally, Zacks Research upgraded shares of Vivani Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 12th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Vivani Medical has an average rating of “Hold” and an average price target of $4.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Susquehanna International Group LLP boosted its stake in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after purchasing an additional 16,200 shares during the period. Citadel Advisors LLC purchased a new position in shares of Vivani Medical in the third quarter worth $26,000. Finally, Panagora Asset Management Inc. bought a new position in shares of Vivani Medical during the second quarter worth $25,000. 6.78% of the stock is owned by hedge funds and other institutional investors.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.